Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eclipse Surgical Technologies

This article was originally published in The Gray Sheet

Executive Summary

Sunnyvale, California-based manufacturer of cardiovascular and surgical laser products anticipates net proceeds of $6.7 mil. from an offering of 1.7 mil. units at a price of $5 per unit, according to a registration statement filed with the Securities and Exchange Commission. The units are comprised of one share of common stock and one class A warrant. The offering is underwritten by Westfield Financial. Eclipse projects that it will use proceeds to fund repayment of notes payable and bridge notes (about $1.9 mil. combined), as well as for the marketing of approved products ($900,000) and the development and expansion of product lines in the cardiovascular, orthopedic, urology, endo-sinus surgery, and spinal surgery markets.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT002759

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel